Giovanni Dothel1,2, Lin Chang1,3, Wendy Shih4, Maria Raffaella Barbaro2, Cesare Cremon2, Vincenzo Stanghellini2, Fabrizio De Ponti2, Emeran A Mayer1,3, Giovanni Barbara2, Catia Sternini1,5. 1. Division of Digestive Diseases, Department of Medicine, CURE: Digestive Diseases Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. 2. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 3. G. Oppenheimer Family Center for Neurobiology of Stress and Resilience, University of California Los Angeles, Los Angeles, CA, USA. 4. Department of Biostatistics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. 5. Department of Neurobiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Abstract
BACKGROUND AND AIMS: The gut immune, cannabinoid, and opioid systems constitute an integrated network contributing to visceral sensation and pain modulation. We aimed to assess the expression of the µ-opioid receptor (MOR), its ligand β-endorphin (β-END), and cannabinoid receptor-2 (CB2 ) in patients with irritable bowel syndrome (IBS) and asymptomatic controls (AC) and their correlation with sex and symptom perception. METHODS: Mucosal biopsies were obtained from the left colon of 31 IBS patients (45% women) with predominant constipation (IBS-C, 9) or diarrhea (IBS-D, 10) or with mixed bowel habits (IBS-M, 12) and 32 AC (44% women) and processed for qRT-PCR, Western blotting, and immunohistochemistry. KEY RESULTS: µ-opioid receptor and CB2 mRNA and protein expression and β-END protein levels were increased in patients with IBS compared to AC (all Ps=0.021). A significant sex by IBS interaction was found in relation to CB2 mRNA expression (P = .003) with women showing a markedly higher expression to men (P = .035). In contrast, in AC, men had higher expression than women (P = .033). β-END, MOR, and CB2 immunoreactivities (IR) were localized to CD4+T cells including EMR-1+ eosinophils and CD31+ T cells but not to mast cells. CONCLUSIONS: The increased expression of MOR, β-END, and CB2 in the mucosa of IBS patients, where they are localized to immune cells, suggests that opioid and cannabinoid systems play an immune-related compensatory role in visceral pain in IBS patients. Further work is necessary to support this hypothesis.
BACKGROUND AND AIMS: The gut immune, cannabinoid, and opioid systems constitute an integrated network contributing to visceral sensation and pain modulation. We aimed to assess the expression of the µ-opioid receptor (MOR), its ligand β-endorphin (β-END), and cannabinoid receptor-2 (CB2 ) in patients with irritable bowel syndrome (IBS) and asymptomatic controls (AC) and their correlation with sex and symptom perception. METHODS: Mucosal biopsies were obtained from the left colon of 31 IBSpatients (45% women) with predominant constipation (IBS-C, 9) or diarrhea (IBS-D, 10) or with mixed bowel habits (IBS-M, 12) and 32 AC (44% women) and processed for qRT-PCR, Western blotting, and immunohistochemistry. KEY RESULTS: µ-opioid receptor and CB2 mRNA and protein expression and β-END protein levels were increased in patients with IBS compared to AC (all Ps=0.021). A significant sex by IBS interaction was found in relation to CB2 mRNA expression (P = .003) with women showing a markedly higher expression to men (P = .035). In contrast, in AC, men had higher expression than women (P = .033). β-END, MOR, and CB2 immunoreactivities (IR) were localized to CD4+T cells including EMR-1+ eosinophils and CD31+ T cells but not to mast cells. CONCLUSIONS: The increased expression of MOR, β-END, and CB2 in the mucosa of IBSpatients, where they are localized to immune cells, suggests that opioid and cannabinoid systems play an immune-related compensatory role in visceral pain in IBSpatients. Further work is necessary to support this hypothesis.
Authors: C Cremon; V Stanghellini; M R Barbaro; R F Cogliandro; L Bellacosa; J Santos; M Vicario; M Pigrau; C Alonso Cotoner; B Lobo; F Azpiroz; S Bruley des Varannes; M Neunlist; D DeFilippis; T Iuvone; S Petrosino; V Di Marzo; G Barbara Journal: Aliment Pharmacol Ther Date: 2017-02-06 Impact factor: 8.171
Authors: Patrick A Hughes; Andrea M Harrington; Joel Castro; Tobias Liebregts; Birgit Adam; Dallas J Grasby; Nicole J Isaacs; Lochana Maldeniya; Chris M Martin; Jenny Persson; Jane M Andrews; Gerald Holtmann; L Ashley Blackshaw; Stuart M Brierley Journal: Gut Date: 2012-07-05 Impact factor: 23.059
Authors: Lucia Marquéz; Juan Suárez; Mar Iglesias; Francisco Javier Bermudez-Silva; Fernando Rodríguez de Fonseca; Montserrat Andreu Journal: PLoS One Date: 2009-09-04 Impact factor: 3.240
Authors: Daniela Ostertag; Sabine Buhner; Klaus Michel; Christian Pehl; Manfred Kurjak; Manuela Götzberger; Ewert Schulte-Frohlinde; Thomas Frieling; Paul Enck; Josef Phillip; Michael Schemann Journal: Front Neurosci Date: 2015-12-16 Impact factor: 4.677
Authors: Stuart M Brierley; Beverley Greenwood-Van Meerveld; Giovanni Sarnelli; Keith A Sharkey; Martin Storr; Jan Tack Journal: Nat Rev Gastroenterol Hepatol Date: 2022-09-27 Impact factor: 73.082
Authors: Agata Szymaszkiewicz; Marcin Talar; Jakub Włodarczyk; Mikołaj Świerczyński; Adrian Bartoszek; Julia Krajewska; Anna Mokrowiecka; Ewa Małecka-Wojciesko; Jakub Fichna; Marta Zielińska Journal: Int J Mol Sci Date: 2022-03-24 Impact factor: 5.923
Authors: Eloísa Salvo-Romero; Cristina Martínez; Beatriz Lobo; Bruno K Rodiño-Janeiro; Marc Pigrau; Alejandro D Sánchez-Chardi; Ana M González-Castro; Marina Fortea; Cristina Pardo-Camacho; Adoración Nieto; Elba Expósito; Danila Guagnozzi; Amanda Rodríguez-Urrutia; Inés de Torres; Ricard Farré; Fernando Azpiroz; Carmen Alonso-Cotoner; Javier Santos; María Vicario Journal: Sci Rep Date: 2020-11-26 Impact factor: 4.379